David C Montefiori Selected Research

Infections

10/2023	Mapping SARS-CoV-2 antigenic relationships and serological responses.
6/2023	Mapping SARS-CoV-2 antigenic relationships and serological responses.
1/2023	A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.
1/2023	Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
1/2023	Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.
1/2023	Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
11/2022	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients.
11/2022	Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.
10/2022	Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
10/2022	Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David C Montefiori Research Topics

Disease

189	Infections 10/2023 - 01/2002
38	Viremia 12/2023 - 03/2002
30	Acquired Immunodeficiency Syndrome (AIDS) 10/2019 - 01/2002
25	COVID-19 02/2024 - 01/2021
23	HIV Infections (HIV Infection) 11/2023 - 08/2003
23	Vaccinia 01/2023 - 01/2002
15	Virus Diseases (Viral Diseases) 10/2021 - 01/2002
9	Disease Progression 01/2020 - 01/2002
8	Vesicular Stomatitis 01/2023 - 09/2004
8	Communicable Diseases (Infectious Diseases) 04/2021 - 01/2003
8	Persistent Infection 08/2015 - 01/2002
5	Breakthrough Infections 01/2022 - 01/2014
3	Pneumonia (Pneumonitis) 02/2021 - 01/2021
2	Erythema 05/2024 - 01/2024
2	Pain (Aches) 05/2024 - 01/2024
2	Neoplasms (Cancer) 10/2021 - 01/2019
2	Edema (Dropsy) 02/2021 - 01/2021
2	Reinfection 01/2021 - 01/2021
2	Hypersensitivity (Allergy) 11/2019 - 10/2007
2	Human Influenza (Influenza) 11/2018 - 01/2014
1	Myalgia 05/2024
1	Headache (Headaches) 05/2024
1	Fatigue 05/2024
1	Anaphylaxis (Anaphylactic Shock) 03/2024
1	Inflammation (Inflammations) 01/2023
1	Pericarditis 01/2022
1	Myocarditis (Carditis) 01/2022
1	COVID-19 related pediatric multisystem inflammatory disease 01/2022
1	Lymphopenia (Lymphocytopenia) 10/2021

Drug/Important Bio-Agent (IBA)

139	VaccinesIBA 05/2024 - 01/2002
58	AntibodiesIBA 01/2023 - 03/2002
56	Neutralizing AntibodiesIBA 12/2023 - 03/2002
37	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2002
33	Proteins (Proteins, Gene)FDA Link 07/2023 - 03/2002
33	Broadly Neutralizing AntibodiesIBA 11/2022 - 02/2012
25	AIDS VaccinesIBA 01/2018 - 01/2002
22	Immunoglobulin G (IgG)IBA 01/2023 - 12/2008
22	EpitopesIBA 01/2023 - 01/2002
15	Monoclonal AntibodiesIBA 12/2023 - 02/2003
14	Glycoproteins (Glycoprotein)IBA 11/2022 - 05/2008
13	2019-nCoV Vaccine mRNA-1273IBA 07/2023 - 08/2021
13	AntigensIBA 01/2021 - 03/2004
13	Immunoglobulin A (IgA)IBA 01/2019 - 02/2012
12	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2002
9	A-Form DNA (A-DNA)IBA 01/2022 - 07/2002
8	GP 140IBA 01/2020 - 05/2008
7	DNA VaccinesIBA 01/2023 - 01/2003
7	env Gene ProductsIBA 01/2022 - 08/2011
7	Peptides (Polypeptides)IBA 07/2020 - 05/2008
6	Messenger RNA (mRNA)IBA 12/2023 - 01/2018
6	RNA (Ribonucleic Acid)IBA 01/2022 - 04/2003
6	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 09/2006
5	BNT162 VaccineIBA 07/2023 - 10/2021
5	CytokinesIBA 02/2021 - 11/2002
5	SAIDS VaccinesIBA 04/2015 - 07/2005
4	Ad26COVS1IBA 07/2023 - 10/2021
4	Immunoglobulins (Immunoglobulin)IBA 12/2021 - 09/2021
3	mRNA VaccinesIBA 01/2024 - 07/2022
3	N-(2-cyanoethylene)urea (BA 1)IBA 11/2022 - 07/2022
3	NucleosidesIBA 04/2021 - 01/2018
3	Fc Receptors (Fc Receptor)IBA 02/2021 - 11/2016
3	aluminum sulfate (alum)IBA 01/2021 - 10/2003
3	Protein Subunits (Protein Subunit)IBA 01/2021 - 04/2004
3	EnzymesIBA 01/2020 - 07/2005
3	AIDSVAXIBA 01/2018 - 08/2010
3	MF59 oil emulsionIBA 01/2018 - 02/2015
3	MVA vaccineIBA 12/2017 - 05/2002
3	Indicators and Reagents (Reagents)IBA 10/2017 - 08/2005
3	Recombinant DNA (Recombinant DNA Research)IBA 02/2012 - 03/2011
3	Viral RNAIBA 07/2006 - 01/2002
2	sortase AIBA 10/2022 - 02/2022
2	Ferritins (Ferritin)IBA 10/2022 - 02/2022
2	DH1047IBA 01/2022 - 04/2021
2	COVID-19 VaccinesIBA 01/2022 - 10/2021
2	Lipid NanoparticlesIBA 04/2021 - 12/2020
2	Blocking AntibodiesIBA 02/2021 - 01/2021
2	Tenofovir (Viread)FDA Link 01/2021 - 07/2006
2	ImmunosorbentsIBA 01/2020 - 07/2008
2	CD40 Ligand (CD40L)IBA 01/2020 - 09/2014
2	Polysaccharides (Glycans)IBA 12/2019 - 02/2012
2	Complement System Proteins (Complement)IBA 01/2017 - 01/2014
2	Immunoglobulin M (IgM)IBA 12/2016 - 12/2008
2	Immunologic Factors (Immunomodulators)IBA 05/2016 - 07/2012
2	Interleukin-2 (IL2)IBA 04/2013 - 03/2005
2	Interleukin-15 (Interleukin 15)IBA 04/2013 - 06/2007
2	Anti-Infective Agents (Microbicides)IBA 06/2010 - 04/2009
2	PhosphatidylserinesIBA 07/2008 - 01/2008
2	Cardiolipins (Cardiolipin)IBA 07/2008 - 01/2008
2	Interleukin-12 (IL 12)IBA 06/2007 - 07/2005
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 03/2024
1	NVX-CoV2373 adjuvated lipid nanoparticleIBA 07/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2023
1	mRNA-1273.214 COVID-19 vaccineIBA 10/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	Toll-Like Receptor 7IBA 01/2022
1	Vorinostat FDA Link 01/2022
1	COVA1-18IBA 10/2021

Therapy/Procedure

6	Therapeutics 01/2022 - 04/2003
2	Art Therapy 10/2020 - 01/2017
1	Injections 01/2024